Kathleen Richton
Fortuna: 11 937 $ al 30/06/2026
Fortuna: 11 937 $ al 30/06/2026
Ms. Kathleen Richton is a Senior VP, Chief Financial & Accounting Officer at enGene Therapeutics, Inc. Ms. Richton was previously employed as a Vice President & Controller by Sunovion Pharmaceuticals, Inc. She received her undergraduate degree from Bentley University and a graduate degree from Bentley University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
ENGENE THERAPEUTICS INC. 0,01 % | 16/07/2026 | 6.900 ( 0,01 % ) | 11 937 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ENGENE THERAPEUTICS INC. | Director Financiero/CFO | 16/07/2026 |
| Empresas | Cargo | Fin |
|---|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Comptroller/Controller/Auditor | 01/07/2023 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals for oncology, CNS, urology and rare diseases | Health Technology |
Bentley University
Bentley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
enGene Holdings, Inc.
enGene Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical-stage biotechnology company that develops, manufactures and sells non-viral genetic medicines | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.